ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 332

Improvement of the Stability of RNA Aptamers Against Interleukin-17A

Natsuki Otaki1, Asako Sasaki1, Shinsuke Hiramoto1, Masakazu Nagamine1, Shigeyuki Mori1, Tomoyoshi Kayo1, Kuniyoshi Hota1, Masayuki Takahashi1, Kazuhiko Haruta2 and Yoshikazu Nakamura3,4, 1Zenyaku Kogyo Co., Ltd., Tokyo, Japan, 22-33-7 Oizumi, Nerima, Zenyaku Kogyo Co., Ltd., Tokyo, Japan, 3Division of RNA Medical Science, The Institute of Medical Science, The University Of Tokyo, Tokyo, Japan, 4RIBOMIC Inc., Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cytokines, IL-6, interleukins (IL) and mouse model, RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose Aptamers are RNA or DNA oligonucleotides selected for their capacity to specifically bind and inhibit the function of a target protein.  The effect is similar to neutralizing antibodies that defend the body against pathogenic antigens.  These potentially therapeutic oligonucleotides often have short half-lives, however, because they are rapidly degraded by nucleases in peripheral blood and excreted by the kidneys.  Here we describe an RNA aptamer against IL-17A that resists degradation in serum and decreases the severity of collagen-induced arthritis in DBA/1 mice.

Methods In vitro assay of serum stability.  After substituting a methoxy group for the 2′ hydroxyl group of ribose, we incubated the RNA aptamers in mouse serum for 0.5 to 72 hours at 37°C.  Controls were incubated in phosphate buffered saline.  Next, samples were added to quenching buffer (8 M urea, 10 mM EDTA, 0.05% bromophenol blue).  Then, the RNA fragments were electrophoresed in 20% polyacrylamide gels that contained 8 M urea in TBE buffer.  Bands were visualized by staining the gel with SYBR Green II.  Each fraction of intact aptamer was normalized to its corresponding control.  Pharmacokinetic studies in mice.  Aptamers were PEGylated with 40-kDa polyethylene glycol and conjugated with 3′-inverted deoxythymidine.  Then, these aptamers were infused as a single bolus into the tail vein of a C57BL/6J mouse at 1 mg/kg.  Aptamer concentrations in plasma were measured by enzyme-linked oligosorbent assay.  Collagen-induced arthritis in mice. Mice were immunized with bovine type II collagen in Freund’s complete adjuvant on day 1.  On day 22, they were boosted with bovine type II collagen in Freund’s incomplete adjuvant.  PEGylated aptamers were injected intraperitoneally at 5 mg/kg once a day from day 22 to day 37.  Objective signs of arthritis for each paw were scored using a scale of 0 to 4.

Results In vitro assay of aptamer 17M-340 for serum stability showed very little degradation after 72 hours incubation.  By contrast, prototype aptamer Apt21-2 or 17M-4 were rapidly degraded within 24 hours.  In vivo, the plasma half-life of 17M-340 was 9.3 hours, more than ten-fold that of 17M-4.  Finally, intraperitoneal injection of 17M-340 but not 17M-4 reduced the objective score of collagen-induced arthritis significantly (p ≤ 0.05). 

Conclusion The anti-IL-17A aptamer is 31-base oligoribonucleotide that forms a stem-loop structure.  Substitution of a methoxy group for the 2′ hydroxyl group of ribose at three positions in the stem and one position in the loop markedly increased stability of the aptamer in vivo.  Our findings raise the possibility that RNA aptamers such as 17M-340 may be effective treatments for patients with chronic inflammatory diseases.


Disclosure:

N. Otaki,

Zenyaku Kogyo Co., Ltd.,

3;

A. Sasaki,

Zenyaku Kogyo Co., Ltd.,

3;

S. Hiramoto,

Zenyaku Kogyo Co., Ltd.,

3;

M. Nagamine,

Zenyaku Kogyo Co., Ltd.,

3;

S. Mori,

Zenyaku Kogyo Co., Ltd.,

1;

T. Kayo,

Zenyaku Kogyo Co., Ltd.,

1;

K. Hota,

Zenyaku Kogyo Co., Ltd.,

3;

M. Takahashi,

Zenyaku Kogyo Co., Ltd.,

1;

K. Haruta,

Zenyaku Kogyo Co., Ltd.,

1;

Y. Nakamura,

TODAI TLO, Ltd.,

7.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-of-the-stability-of-rna-aptamers-against-interleukin-17a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology